Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment
about
Protein calorie malnutrition, nutritional intervention and personalized cancer care.Tissue-protective activity of selenomethionine and D-panthetine in B16 melanoma-bearing mice under doxorubicin treatment is not connected with their ROS scavenging potential.The times they are a-changin': the Cachexia Conference goes annual.Muscle wasting and cachexia in heart failure: mechanisms and therapies.Doxorubicin inhibits muscle inflammation after eccentric exercise.Novel therapeutic options for cachexia and sarcopenia.Muscle wasting in heart failure : The role of nutrition.Publication trends in cachexia and sarcopenia in elderly heart failure patients.Single-nucleotide polymorphisms in cachexia-related genes: Can they optimize the treatment of cancer cachexia?Welcome to the ICD-10 code for sarcopenia.Growth differentiation factor-15 as a prognostic biomarker in cancer patients.Is cardiac wasting accompanied by skeletal muscle loss in breast cancer patients receiving anticancer treatment?Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.Aerobic exercise training rescues protein quality control disruption on white skeletal muscle induced by chronic kidney disease in rats.An analysis of the types of recently published research in the field of cachexia.Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia.Acute Sarcopenia Secondary to Hospitalisation - An Emerging Condition Affecting Older Adults.Therapeutic considerations of sarcopenia in heart failure patients.Wasting away: How to treat cachexia and muscle wasting in chronic disease?Muscle wasting and sarcopenia in heart failure and beyond: update 2017.Establishing a clinical phenotype for cachexia in end stage kidney disease - study protocol.Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine.Cachexia therapies - the need to take a broader look.Creatine ( methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA.Role of microRNAs in wasting in heart failure.Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia.Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018Developing a toolkit for the assessment and monitoring of musculoskeletal ageing
P2860
Q33618955-8804EA9E-E47F-42ED-AA66-4DD71BC6DCE4Q33619895-FEC452C8-2FFA-44CB-9139-123DCCF9BC8BQ34521653-D2F0A007-C579-4A53-BC1E-EACFEFBBB4C7Q34681621-F2DF0037-D031-45F2-9ADE-0735C987BD8FQ37734801-5348A7B5-2775-4FD4-98CD-8A179A2CA8DBQ38887581-2E30C915-DBAC-42E6-90AB-C39C9594B0F1Q38985792-4E9741B3-45E1-49C8-88AE-547BDD04B3DDQ39019268-D251E110-7478-422A-B7AC-68C445D2DB0AQ42336582-791310C9-50A2-4723-88B6-C52876AD8A1BQ42366308-6E4E71F2-8086-4C41-9A17-B31D32389840Q42770577-D0B37DBE-F3E1-4A47-9C48-53B0156F93E1Q45148920-C55F7786-3CA0-4B2A-9A96-8EDCDD3D0ECDQ46213438-508F13B4-EAA8-4C61-BD63-73FACB2EDE9FQ47117911-A01D4C8F-2F25-45D3-B966-D9A90E0FE56DQ47132964-1929951D-5D89-4282-AA8E-5E14D573E87EQ47266746-84632FCC-21C0-4669-BC61-33B1C9E49042Q47568983-9C69A996-5B9F-46A9-9487-F25DBD1A6489Q47605033-44D538A5-DCFA-4F24-94A8-2D2CA5E3868EQ47698223-EABC5C92-4576-4417-82ED-61C740175EA9Q47747144-33A2C62A-1EDD-415F-B2AE-4753B7425E88Q48743369-242C9752-6AA4-4388-B60C-C4A79D6EC3BEQ49183956-4CB807C0-DDB1-468E-AA9A-5290DB20194AQ49194938-CF1548BE-1ABE-4494-B89B-5DF7B1DB3382Q49376536-914C51C7-6B00-4098-AD64-948B0D422355Q49586619-183BCE5E-9FDA-440F-9328-AB10335D189CQ50241195-E32B7EE2-DD5E-4285-A0A0-E98CAFC6EA2BQ52836641-8BB8E0E1-897E-4AC6-A131-003B67262D88Q55646811-6F1310F2-8E26-4B6F-8560-A11C909424F9Q57476138-21209537-02DA-4E8F-8A42-3D1DD3EB3982Q58293684-DB3BB201-D152-4CF4-9FBD-3EE8369E0B51
P2860
Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@ast
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@en
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@nl
type
label
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@ast
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@en
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@nl
prefLabel
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@ast
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@en
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@nl
P2093
P2860
P3181
P356
P1476
Loss of muscle mass: current d ...... ed on biomarkers and treatment
@en
P2093
Jochen Springer
Masaaki Konishi
Nicole Ebner
P2860
P304
P3181
P356
10.1002/JCSM.12082
P407
P577
2015-11-18T00:00:00Z